Navigation Links
ActiGraph Announces New Scientific Affairs and Data Management Division

ActiGraph, the leading provider of medical-grade wearable activity and sleep monitoring solutions for the global scientific community, announced today the establishment of a new Scientific Affairs and Data Management division. A primary focus of this new division is to foster and support scientific collaborations with ActiGraph’s academic and pharmaceutical industry partners to advance the development of meaningful clinical trial endpoints based on high-resolution raw accelerometry data.

Guided by the novel endpoint development framework released by the Clinical Trials Transformation Initiative (CTTI) in 2017, ActiGraph’s Scientific Affairs and Data Management division, headed by Director Tyler Guthrie, will facilitate joint research and development projects involving corporate partners and subject matter experts from within the company’s global network of over 1000 academic partners. With extensive accelerometry experience in a wide variety of specific chronic disease populations, ActiGraph’s academic subject matter experts bring a wealth of practical knowledge and analytic expertise to projects exploring new meaningful clinical endpoints and better ways to measure existing endpoints using accelerometry. ActiGraph is also exploring additional partnerships to develop clinical endpoints based on new methods, including artificial intelligence (AI) and machine learning.

“The Scientific Affairs and Data Management division was formed as a direct response to the growing need from pharmaceutical sponsors and CROs for scientifically validated digital endpoints,” said Jeff Arnett, ActiGraph CEO. "We have already been tapping into the expertise of our academic subject matter experts and internal scientific team for existing clinical trial projects. By establishing this focused division, we can accelerate the development, validation, and implementation of novel digital clinical endpoints that could improve future trials.”

ActiGraph’s announcement comes at a time when the use of digital tools to capture quantifiable measures of biology and health is rapidly increasing across the clinical trials landscape. “We are delighted that pioneering companies like ActiGraph are helping lead the way in the development and application of digital biomarkers to a wide range of clinical conditions,” said E. Ray Dorsey, M.D., Editor-and-Chief for the Digital Biomarkers scientific journal.

ActiGraph’s establishment of the Scientific Affairs and Data Management division precedes the upcoming launches of two new products within its clinical trials technology ecosystem. In August 2018, the company will release CentrePoint 3.0, a major update to its software platform that includes highly anticipated raw data analytic capabilities. In late Q3 2018, ActiGraph will launch the patient-centric CentrePoint Insight Watch, a triaxial accelerometry watch with a 30-day battery life, designed specifically for use in clinical drug trials. The CentrePoint Insight Watch captures continuous, high-resolution raw acceleration data and supports near real-time remote patient monitoring when used in combination with ActiGraph’s CentrePoint home data hub or mobile application.

About ActiGraph
ActiGraph is the leading provider of medical-grade physical activity and sleep monitoring solutions for the global scientific community. ActiGraph’s wearable actigraphy monitors and robust analytics platform have been widely used to quantify human movement in academic and population health research for nearly two decades. In recent years, the company’s monitoring solutions have been steadily adopted by biopharma and life sciences organizations seeking to capture real-world objective outcomes related to physical activity, mobility, and sleep behavior for patients enrolled in clinical trials.

Read the full story at

Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved

Related biology news :

1. Merck Animal Health announces Vetsulin
2. AAPS announces 2013 National Biotechnology Conference award winners
3. PLOS announces Accelerating Science Award Program
4. DFG announces recipients of 2013 Heinz Maier-Leibnitz Prize
5. Missouri Botanical Garden program announces collaboration with LHerboretum
6. Scripps Research announces research & license agreement with Janssen Pharmaceuticals
7. Chiltern Announces The Promotion Of Alecia Barbee To VP, Global Biometrics
8. DigitalPersona Announces U.are.U Software Development Kit (SDK) for Android Applications
9. PatientStream announces the industrys first Multilingual family waiting room board
10. Wiley announces increase in Impact Factors
11. Xyngular Announces the Launch of its New Xyng Enhanced Formula
Post Your Comments:
(Date:8/14/2019)... ... August 14, 2019 , ... Representatives with MyBioGate announced that China Focus@Biotech Week ... , “We help innovative projects connect with Chinese pharma and investors in healthcare innovation,” ... on to explain that as a part of Biotech Week Boston – the annual ...
(Date:8/14/2019)... ... August 13, 2019 , ... Join Anguraj Sadanandam, PhD, Team ... Cancer Research (ICR) in a live webinar on Wednesday, September 4, ... and companion diagnostic development including machine learning approaches in different gastrointestinal cancers and ...
(Date:8/9/2019)... ... ... With a demand in healthcare to lower unneeded emergency room visits and provide ... in the coming years, according to a new report on the industry by market ... is a detailed look at the current state of these healthcare outlets, including the ...
Breaking Biology News(10 mins):
(Date:9/17/2019)... ... 2019 , ... A new episode of Advancements with Ted ... local listings for more information on this program. , The show will explore ... Singapore dedicated to developing advanced diagnostic technologies for the masses. Viewers will learn ...
(Date:9/11/2019)... PRUSSIA, Pa. (PRWEB) , ... September 09, 2019 ... ... problems for life sciences companies and government agencies, announced that its president and ... invitation-only group of successful business leaders. , The Forbes Council accepted Gallivan based ...
(Date:9/11/2019)... ... September 10, 2019 , ... An upcoming episode of Advancements ... in genome sequencing analysis. Check your local listings for more information. , Advancements ... & Consulting and will explore its revolutionary pathogenic DNA analysis technology, which predicts ...
(Date:9/9/2019)... ... September 09, 2019 , ... Visikol CEO Dr. Michael Johnson recently gave ... how best to characterize 3D cell culture models. The inherent problem of characterizing 3D ... and opaque to image through and therefore traditional wide-field or even confocal microscopy only ...
Breaking Biology Technology: